Linked Life Data

6635518

Source:http://linkedlifedata.com/resource/pubmed/id/6635518

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1983-12-20
pubmed:abstractText
Forty patients wtih pituitary adenomas, i.e. 22 prolactinomas, 13 acromegalies, 5 non-secreting adenomas, were submitted to bromocriptine therapy 19.3 +/- 1.7 mg/day (mean +/- SEM) (range 7.5-40.0 mg/day) for 5 to 41 months (10.1 +/- 1.31). Remission of the tumoral mass was documented by air tomograms (PETG) or computerized tomograms (CT) in all but one prolactinomas and in 2 mixed HGH and PRL-secreting adenomas. Six empty sella syndromes (ESS) were produced, 4 of them during primary chemotherapy. Serum PRL decreased to normal in all but 3 prolactinomas, and serum HGH levels in 5 out of 13 acromegalies. Bromocriptine withdrawal was followed by a rapid increase of serum PRL into the pathological range, without a rapid reexpansion of the tumoral remnants: GT or surgical exploration of 4 cases, remitted until ESS showed a minimal evolution along 8 months after bromocriptine withdrawal. It is suggested that the antitumoral effect of bromocriptine is specific to lactotrophic cells and at least partially irreversible.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0253-1801
pubmed:author
pubmed:issnType
Print
pubmed:volume
21
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
157-68
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:articleTitle
Bromocriptine treatment of pituitary adenomas. Evaluation of withdrawal effect.
pubmed:publicationType
Journal Article